New drug candidates and therapeutic targets for tuberculosis therapy

Ying Zhang, Katrin Post-Martens, Steven Denkin

Research output: Contribution to journalReview articlepeer-review

Abstract

Despite advances in chemotherapy and the BCG (Bacillus Calmette- Guérin) vaccine, tuberculosis remains a significant infectious disease. Although it can be cured, the therapy takes at least 6-9 months, and the laborious and lengthy treatment brings with it dangers of noncompliance, significant toxicity and drug resistance. The increasing emergence of drug resistance and the problem of mycobacterial persistence highlight the need to develop novel TB drugs that are active against drug resistant bacteria but, more importantly, kill persistent bacteria and shorten the length of treatment. Recent new and exciting developments in tuberculosis drug discovery show good promise of a possible revolution in the chemotherapy of tuberculosis.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalDrug Discovery Today
Volume11
Issue number1-2
DOIs
StatePublished - Jan 2006

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'New drug candidates and therapeutic targets for tuberculosis therapy'. Together they form a unique fingerprint.

Cite this